Hepatitis C virus virology and new treatment targets

  title={Hepatitis C virus virology and new treatment targets},
  author={Volker Meier and Giuliano Ramadori},
  journal={Expert Review of Anti-infective Therapy},
  pages={329 - 350}
  • V. Meier, G. Ramadori
  • Published 1 April 2009
  • Medicine, Biology
  • Expert Review of Anti-infective Therapy
Hepatitis C virus (HCV) infection is the leading cause of chronic liver disease. An estimated 130 million people worldwide are persistently infected with HCV. Almost half of patients who have chronic HCV infection cannot be cured with the standard treatment consisting of pegylated IFN-α and ribavirin. For those patients who do not respond to this standard antiviral therapy, there is currently no approved treatment option available. Recent progress in structure determination of HCV proteins and… 
Study on HCV direct acting drugs in treatment of chronic hepatitis C
The development of new models and tools has led to the discovery and clinical development of a large number of new anti­hepatitis C virus (HCV) drugs, and cure rates have increased to more than 90 percent.
Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
  • H. Qashqari, Amany Al-Mars, I. Qadri
  • Biology, Medicine
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  • 2013
Natural History, Pathogenesis, and Prevention of HCV Infection
The prevention of HCV rests upon the screening of individuals at highest risk for HCV infection, coupled with appropriate risk reduction strategies to reduce viral transmission and appropriate treatment ofHCV infection to reduce the potentially infectious reservoir.
The Genetic and Molecular Studies of Hepatitis C Virus: A Review
The present review looks at the genetic and molecular nature of Hepatitis c virus with the view to provide more information about its biology which may be useful to the present and feature researchers.
Perspectives on the management of chronic hepatitis B and C
This special edition of Expert Review of Anti-infective Therapy on viral hepatitis contains expert reviews of chronic hepatitis B and C, including new agents, such as telbivudine, hepatitis B immunoglobulin, and HBIG in preventing reinfection in liver transplantations.
Variations in DEPDC5 gene and its association with chronic hepatitis C virus infection in Saudi Arabia
Genetic variations in DEPDC5 gene region may influence HCV-associated liver cirrhosis and/or HCC development, and subjects with the T allele of both SNPs appeared to have a lower susceptibility toHCV-related Cirrhosis/HCC.
Levels of interleukins 12 (IL-12) and 13 (IL-13), hepatitis B and C serology, and blood cultures among acute myeloid leukemia (AML) patients in Egypt
IL-12 and IL-13 should be further tested in large-scale studies to provide future immunotherapy against AML, and fungemia cases showed higher IL-12 values than bacteremia cases.
Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
Locteron merits further clinical investigation as a hepatitis C therapy suitable for dosing once per 2 weeks, and more than 2-fold that of PEG-IFN-alpha2b.
Auricularia auricula increases an apoptosis in human hepatocellular carcinoma cells via a regulation of the peroxiredoxin1.
The findings suggest that A. auricula is a potent inducer of apoptosis in HCC cells viaPRDX1-inhibition pathways, and regulation mechanism of PRDX1 in H CC has a proliferative effect and play a role in cancer development or progression.


The Scientific Challenge of Hepatitis C
Although to date no one has been able to grow HCV reliably in a laboratory culture of cells, on page 110, researchers describe a new system for culturing HCV9s RNA.
Replication of hepatitis C virus.
This review summarizes the current knowledge about HCV replication and describes attempts pursued in the last few years to establish efficient and reliable cell culture systems.
Immunology of hepatitis C virus infection
Recent studies in humans and chimpanzees have significantly enhanced understanding of the interaction between HCV and the host’s immune system, and the possible mechanisms of how HCV establishes chronic infection are discussed.
Binding of hepatitis C virus to CD81.
Recombinant molecules containing this loop bound HCV and antibodies that neutralize HCV infection in vivo inhibited virus binding to CD81 in vitro.
Hepatitis C virus entry: Molecular biology and clinical implications
The impact of recently identified viral and host cell factors for HCV attachment and entry is summarized and clinical implications of this important process for the pathogenesis of HCV infection and novel therapeutic interventions are discussed.
Antiviral therapy for chronic hepatitis C: past, present, and future
Antiviral therapy for chronic hepatitis C has dramatically advanced since the discovery of the hepatitis C virus (HCV) in 1989 and the introduction of interferon (IFN) monotherapy in the early 1990s, with new types of anti-HCV agents needed for those patients that do not respond to combination therapy.
Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti‐hepatitis C virus strategy
Using a cell culture‐based screening, chemical genetics analysis identified CyPB as a cellular cofactor of HCV genome replication and a target for novel anti‐HCV agents.
Complete Replication of Hepatitis C Virus in Cell Culture
A full-length HCV genome that replicates and produces virus particles that are infectious in cell culture (HCVcc) is described, suggesting that this in vitro system will aid in the search for improved antiviral compounds.